Clinical Trial

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2015-06-24; most recent amendment 2017-07-31.
Status change: Completed → Active, Not Recruiting 2016-02-21
Trial Details
NCT Number NCT02482454
Lead Sponsor The First People's Hospital of Changzhou
Conditions Cholangiocarcinoma
Enrollment 50 participants
Start Date 2012-07
Primary Completion 2030-07 (estimated)
Study Completion 2033-07 (estimated)
Updated on ClinicalTrials.gov 2017-08-01